Answers are grounded in this paper and cite their sources.
A new class of agents termed vasopeptidase inhibitors (VPIs) have the potential to be the next major advance in the treatment of hypertension, congestive heart failure (CHF) and related cardiovascular diseases. VPIs are single molecular compounds that inhibit two distinct zinc metalloproteases: neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE). Vasopeptidase inhibition attenuates the formation of angiotensin II while potentiating endogenous levels of atrial natriuretic peptide (ANP) and bradykinin (BK). The combined effect has proven to be highly efficacious for the treatment of hypertension and CHF in experimental animal models and recently in man. This review highlights recent advances and disclosures over the last three years in this field.
No takes yet. Share an insight, caveat, or question.
Robl et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: